Nivolumab and Eribulin in HER2 Negative Metastatic Breast Cancer
Status:
Active, not recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
Cancer therapeutics such as chemotherapy may modulate tumor/immune-system interactions in
favor of the immune system. Chemotherapy can result in tumor cell death with a resultant
increase in tumor antigen delivery to antigen-presenting cells. Therefore, combining
immunotherapy (Nivolumab) with chemotherapy (Eribulin) is a promising anti-cancer strategy.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Seoul National University Hospital
Collaborators:
Eisai Korea Eisai Korea Inc. Korean Cancer Study Group (KCSG) Ono pharmaceutical Korea Seoul National University Bundang Hospital